Sun Pharma acquires 3 brands to strengthen anti-inflammatory portfolio
Acquired from Aksigen Hospital, Disperzyme, Disperzyme-CD and Phlogam have been approved by the Drugs Controller General of India for post-operative inflammation in patients undergoing minor surgery and dental procedures
Nifty has broken down from its consolidation range and slipped below its 100-day exponential moving average (EMA) of 17,900 levels, which was being defended for the past 23 sessions. The short-term moving averages are in a falling mode, which indicates the bearish momentum could continue in the upcoming week.
FY24 should see improvement in margins for pharma sector: Aditya Khemka
However, in FY24 what we believe is that the government will again allow pharma companies to take price increases anywhere in the range of 12% to 13% on the NLEM drugs and the non-NLEM drugs again about up to 10% which will help the price realisation in terms of growth.
Nithya Balasubramanian on 2 pharma names to bet on besides Sun & Cipla
“Coming to the complex generics opportunity, Cipla and Lupin are most exposed. We like Cipla more than Lupin because at least in the near term, there are multiple assets waiting to play out. For Cipla this year, we are hoping to see generic Advair, generic Abraxane which is most likely in the price but beyond that, there will be a generic Qvar, there will be a generic Teriparatide and potentially a generic Flovent as well.”
Expect 2023 to be a stable year with a lot of bottom-up opportunities: Rajesh Kothari
“2023 was an overall good year. We expect a good stable year and from here, a lot of bottom up opportunities will come up in India across various sectors. If you look at the second quarter of FY23, it is proving that data point. I think there are many bottom up opportunities from here on. It is just the beginning of the growth cycle.”
Hot Stocks: Brokerages on Jubilant FoodWorks, Sun Pharma and Federal Bank
"The bank has managed asset quality well throughout the epidemic, and the bank intends to aggressively extend its footprint through partnerships with fintech companies as well as physical expansion. We value the company at 12.8x FY23 EPS to arrive at the target of 161," the note said.
Hot Stocks: Brokerages on Bharat Forge and Sun Pharma; JPMorgan see 28% upside in PNB
BofA Securities maintained its buy rating on Sun Pharma with a target of Rs 1,000. Flattish llumya trend and the company is waiting for Winlevi Rx to pick up. Sun Pharma's global specialty revenue growth was 30% in H1FY23, this was largely aided by llumya ramp-up. Regulatory overhang continues.
Shares of Sun Pharmaceutical on Thursday lost up to 3.5% to hit the day's low at Rs 981.50 in morning trade after the company told stock exchanges that its Halol facility in Gujarat had been placed under 'Import Alert' by USFDA.We now wish to inform you that the Company received a communication from the USFDA stating that the facility has been listed under Import Alert," Sun Pharma said in a regulatory filing.
Are midcaps a good buy in this market? Neeraj Dewan of Quantum Securities answers
Neeraj Dewan: Yes, definitely. There are still opportunities there. One such sector is the construction and infrastructure sector, where I do not think you are trading at high valuations right now. There are still stocks trading below their average trading multiples, and there is definitely a good order book.
Chart Analysis for Study Purpose: A breakout could be seen in #SUNPHARMA for tomorrow 30th Nov. We dont see a good volume today in increasing order, so breakout chances are less... but keep an eye... If it cross above 1053 and holds, we could see a good rally in this stock...
See value in 2 insurance stocks; no value in Bikaji Foods: Sandip Sabharwal
“There is no value in Bikaji Foods. The entire speculative activity in the market has shifted from the new generation technology stocks where people have lost a lot of money to these newly listed companies. Any long-term investor should just ignore these moves. HDFC Life seems to have value as it has the potential of giving double digit returns over the next one year. ICICI Pru Life got sold out very substantially right from Rs 620-630 odd to Rs 460 in a straight line,”